CD8A and neoplasm: Several types of CD8+ T cell-targeting immunotherapies, including immune checkpoint inhibitors (ICIs), chimeric antigen receptor-modified T cells (CAR-T), and T-cell receptor-gene-engineered T cells (TCR-T), show remarkable efficacy in treating certain neoplasms.